OrthoPediatrics (NASDAQ:KIDS – Get Free Report) posted its earnings results on Thursday. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.04, FiscalAI reports. The firm had revenue of $59.36 million for the quarter, compared to analyst estimates of $58.29 million. OrthoPediatrics had a negative return on equity of 6.70% and a negative net margin of 16.77%.
Here are the key takeaways from OrthoPediatrics’ conference call:
- Raised 2026 guidance to a revenue range of $263M–$267M (11%–13% growth), and reaffirmed ~$25M adjusted EBITDA with a goal of full-year free cash flow breakeven — management called this a sign of sustained execution.
- Early beta launches — including 3P Hip, VerteGlide, and TRAXIO — are generating strong demand; the company expects these products to drive higher ASPs, margin expansion, and improved capital efficiency as set deployments scale.
- OPSB (specialty bracing and clinics) grew >20% in Q1, with clinic expansion ahead of plan and a target of 27 territories by end of 2027, supporting both revenue and profitability upside.
- International revenue accelerated (>20% growth) and the business received full EU MDR approvals for key portfolios, enabling broader European commercialization and stabilizing LATAM through the Brazil distributor acquisition.
- While Q1 revenue was $59.4M (+13%) and adjusted EBITDA turned positive ($2.2M), the company still reported a GAAP net loss of $0.45/share, used $5M free cash flow in Q1, and is keeping guidance and set‑deployment conservative, which could limit near-term upside.
OrthoPediatrics Price Performance
KIDS traded up $0.62 during trading on Friday, hitting $15.68. The company’s stock had a trading volume of 221,055 shares, compared to its average volume of 159,448. The company has a current ratio of 5.55, a quick ratio of 2.65 and a debt-to-equity ratio of 0.28. OrthoPediatrics has a twelve month low of $14.42 and a twelve month high of $23.70. The business’s fifty day simple moving average is $16.73 and its 200 day simple moving average is $17.28. The firm has a market capitalization of $402.74 million, a price-to-earnings ratio of -9.28 and a beta of 1.16.
Analyst Upgrades and Downgrades
Read Our Latest Stock Report on OrthoPediatrics
Insider Buying and Selling
In other OrthoPediatrics news, General Counsel Daniel J. Gerritzen sold 8,614 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $17.25, for a total value of $148,591.50. Following the sale, the general counsel directly owned 149,533 shares of the company’s stock, valued at approximately $2,579,444.25. This trade represents a 5.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gregory A. Odle sold 8,433 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $17.25, for a total value of $145,469.25. Following the completion of the sale, the insider directly owned 187,735 shares in the company, valued at approximately $3,238,428.75. The trade was a 4.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 58,171 shares of company stock valued at $1,003,450 in the last 90 days. Corporate insiders own 32.70% of the company’s stock.
Institutional Trading of OrthoPediatrics
Institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in OrthoPediatrics by 6.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after acquiring an additional 645 shares during the last quarter. Russell Investments Group Ltd. increased its stake in OrthoPediatrics by 433.1% during the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after acquiring an additional 1,139 shares during the last quarter. BNP Paribas Financial Markets increased its stake in OrthoPediatrics by 60.2% during the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,235 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in OrthoPediatrics by 5,226.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after acquiring an additional 2,561 shares during the last quarter. Finally, Barclays PLC increased its stake in OrthoPediatrics by 10.7% during the fourth quarter. Barclays PLC now owns 26,405 shares of the company’s stock worth $469,000 after acquiring an additional 2,561 shares during the last quarter. 69.05% of the stock is owned by institutional investors and hedge funds.
Key OrthoPediatrics News
Here are the key news stories impacting OrthoPediatrics this week:
- Positive Sentiment: Q1 results beat consensus on revenue and per‑share loss was slightly better than some street estimates; revenue was $59.36M and EPS was ($0.42), which topped certain analyst estimates and supports the upbeat tone. GlobeNewswire: Q1 2026 Results
- Positive Sentiment: Management raised FY‑2026 revenue guidance to $263.0M–$267.0M (vs. consensus ~$264.3M), signaling confidence in sales trajectory for the year. Press Release: Guidance Raise
- Positive Sentiment: BTIG reaffirmed a Buy rating and set a $24 price target (material upside vs. current levels), which can attract momentum buyers and funds that follow analyst targets. Benzinga: BTIG Reaffirmation
- Neutral Sentiment: Company expanded its specialty bracing portfolio with the TRAXIO Halo Gravity Traction System — a product launch that supports longer‑term sales diversification but has limited immediate revenue impact. GlobeNewswire: Product Launch
- Neutral Sentiment: Full Q1 earnings call transcript and analyst write‑ups provide detail on trends, mix and geographic performance — useful for investors doing deeper due diligence but not headline‑moving by themselves. Seeking Alpha: Q1 Transcript Zacks: Metrics Analysis
- Negative Sentiment: Despite the revenue beat, the company remains unprofitable (negative net margin ~16.8% and negative ROE), and some outlets note EPS comparisons that were worse vs. certain estimates — keeping profitability concerns front and center for investors. Zacks: EPS & Metrics
- Negative Sentiment: The stock is trading below its 50‑ and 200‑day moving averages, which can limit near‑term technical upside and make the name more sensitive to any negative news or guidance revisions. MarketBeat: Stock Data
About OrthoPediatrics
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
See Also
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
